Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Neutralization of SARS-CoV-2 B...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China

Bibliographic Details
Main Authors: Xun Wang, Shuai Jiang, Shujun Jiang, Xiangnan Li, Jingwen Ai, Ke Lin, Shiyun Lv, Shixuan Zhang, Minghui Li, Jixi Li, Lili Dai, Zixin Hu, Wenhong Zhang, Yanliang Zhang, Pengfei Wang
Format: Article
Language:English
Published: Nature Publishing Group 2023-06-01
Series:Cell Discovery
Online Access:https://doi.org/10.1038/s41421-023-00569-5
  • Holdings
  • Description
  • Similar Items
  • Staff View
Description
ISSN:2056-5968

Similar Items

  • Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
    by: Peter J. Halfmann, et al.
    Published: (2024-03-01)
  • Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination
    by: Bin Ju, et al.
    Published: (2023-06-01)
  • Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
    by: Lorenza Bellusci, et al.
    Published: (2023-04-01)
  • Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
    by: Fanglei Zuo, et al.
    Published: (2023-04-01)
  • Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
    by: Kyle C. Molina, et al.
    Published: (2024-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs